| ORIGINAL ARTICLE |
|
| Year : 2001 | Volume
: 17
| Issue : 2 | Page : 127-131 |
|
|
Ten years' experience with adjuvant intravesical immunotherapy in management of superficial transitional cell carcinoma of urinary bladder - a review
NK Mohanty, Alok K Jha, S Saxena, Sujit Kumar, RP Arora
Department of Urology and Institute of Pathology, Safdarjang Hospital, New Delhi, India
Correspondence Address:
N K Mohanty
D-II/87, West Kidwai Nagar, New Delhi - 110 023
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
The incidence of Transitional Cell Carcinoma (TCC) of urinary bladder is increasing worldwide. Patients with superficial TCC of urinary bladder can have a survival period of 10 years if they are detected at an early stage and appropriate intravesical adjuvant immunotherapy is instilled in time.
A total number of 440 patients of superficial TCC were instilled intravesically BCG & Interferon a-2b as single drug or in combination and followed up.
BCG though was most efficient, had high toxic rate while Interferon α-2b was expensive, whereas a low dose combination therapy of both showed excellent result in reducing tumor recurrences & prolonging disease progression free interval.
The author reviews his experience of 10 years in management of these malignancies with intravesical immunotherapy and concludes that a low dose BCG (60mg) with Interferon α-2b (5 million IU) has shown to be very effective in reducing tumor recurrences, prolonging disease-progression-free interval with a very low toxicity in such patients. To achieve this a periodic maintenance dose therapy is absolutely necessary. |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
